Related Experiment Videos
[Hemodynamic effects of one administration of l-dopa in patients with left ventricular heart failure (introductory
P Leszek1, T Zieliński, J Korewicki
1II Kliniki Wad Serca Instytutu Kardiologii, Warszawie.
Insights
Levodopa (L-dopa) administration improved cardiac function in men with severe congestive heart failure by increasing cardiac index and stroke volume index. This treatment also significantly reduced systemic vascular resistance, offering a potential therapeutic avenue.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Congestive heart failure (CHF) is a debilitating condition with limited treatment options.
- Severe CHF is characterized by impaired cardiac output and elevated vascular resistance.
- Understanding novel pharmacological interventions is crucial for managing advanced heart failure.
Purpose:
- To investigate the hemodynamic effects of Levodopa (L-dopa) in patients with severe congestive heart failure.
- To assess changes in cardiac output, filling pressures, and systemic vascular resistance following L-dopa administration.
- To evaluate the safety and efficacy of L-dopa as a potential treatment for advanced heart failure.
Summary:
- Eight men with severe congestive heart failure (NYHA class III-IV) received escalating doses of oral Levodopa (L-dopa).
- Hemodynamic parameters, including cardiac index, stroke volume index, and systemic vascular resistance, were measured via right heart catheterization before and after L-dopa administration.
- L-dopa treatment resulted in a significant increase in cardiac index and stroke volume index, alongside a marked reduction in systemic vascular resistance.
Impact:
- Levodopa (L-dopa) demonstrates potential as a therapeutic agent for improving cardiac performance in severe congestive heart failure.
- The findings suggest a novel pharmacological approach to managing advanced heart failure by reducing afterload.
- Further research is warranted to explore long-term efficacy and safety in a broader patient population.
Abstract:
The study group consisted of 8 men with congestive heart failure. They ranged in age from 33 do 63 years (mean 48). Three patients were in class III NYHA, five in class IV. Idiopathic cardiomyopathy was diagnosed in 6 patients, one individual displayed ischemic heart disease and one patient was after mitral and aortic-valve replacement despite a normally functioning prosthetic valve. L-dopa was given orally beginning with 250 mg every six hours until a total daily dose of 4.0 g was achieved with no side effects (patients additionally received 50 mg of pyridoxine hydrochloride). Afterwards L-dopa was withheld for 24-36 hours. Having completed this washout period, patients underwent right heart catheterization, with placement of a balloon-tipped thermodilution catheter in a pulmonary artery, so that balloon inflation allowed recording of the pulmonary capillary wedge pressure. Right atrial and pulmonary arterial pressures were monitored continuously. Systemic arterial pressure was measured by mercury manometer. Cardiac output was determined by the thermodilution technique. Rest and effort hemodynamic measurements were repeated before and one, three hours after administration of 1-dopa. The base-line hemodynamic values were consistent with the clinical presentation of severe congestive heart failure. The average cardiac index (CI-1/min/m2--rest--1.93; 25 Watt-3.1) and stroke volume index (SVI-m1/m2--rest--22.2; 25 Watt-32.0) were markedly lowered. Left ventricular filling pressure and pulmonary artery pressure were elevated. The systemic vascular resistance was significantly increased (SVR -j.W.--rest--22.7; 25 Watt-14.2). Administration of 1-dopa resulted in the increase in cardiac index and stroke volume index accompanied by a substantial reduction in systemic vascular resistance.(ABSTRACT TRUNCATED AT 250 WORDS)